PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Franklin Genomic Advancements ETF (HELX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

ETF Info

ISINUS35473P5200
CUSIP35473P520
IssuerFranklin Templeton
Inception DateFeb 25, 2020
RegionDeveloped Markets (Broad)
CategoryHealth & Biotech Equities, Actively Managed
Index TrackedNo Index (Active)
Asset ClassEquity

Asset Class Size

Multi-Cap

Asset Class Style

Growth

Expense Ratio

The Franklin Genomic Advancements ETF has a high expense ratio of 0.50%, indicating higher-than-average management fees.


0.50%1.00%1.50%2.00%0.50%

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with HELX

Franklin Genomic Advancements ETF

Popular comparisons: HELX vs. BBH, HELX vs. FBT, HELX vs. IDNA, HELX vs. BMEZ, HELX vs. WDNA, HELX vs. IBB, HELX vs. IBBQ, HELX vs. ARKG, HELX vs. XBI, HELX vs. SOXX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Franklin Genomic Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%80.00%OctoberNovemberDecember2024FebruaryMarch
37.22%
77.86%
HELX (Franklin Genomic Advancements ETF)
Benchmark (^GSPC)

S&P 500

Returns By Period

Franklin Genomic Advancements ETF had a return of 7.51% year-to-date (YTD) and 9.21% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date7.51%10.16%
1 month-0.07%3.47%
6 months15.58%22.20%
1 year9.21%30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-2.26%7.99%
2023-1.45%-7.95%-10.04%9.31%9.36%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
HELX
Franklin Genomic Advancements ETF
0.61
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Franklin Genomic Advancements ETF Sharpe ratio is 0.61. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
0.61
2.79
HELX (Franklin Genomic Advancements ETF)
Benchmark (^GSPC)

Dividends

Dividend History

Franklin Genomic Advancements ETF granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.


PeriodTTM2023202220212020
Dividend$0.00$0.00$0.00$0.12$0.05

Dividend yield

0.00%0.00%0.00%0.24%0.12%

Monthly Dividends

The table displays the monthly dividend distributions for Franklin Genomic Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.12
2020$0.05

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-43.60%
0
HELX (Franklin Genomic Advancements ETF)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Franklin Genomic Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Franklin Genomic Advancements ETF was 56.33%, occurring on Oct 30, 2023. The portfolio has not yet recovered.

The current Franklin Genomic Advancements ETF drawdown is 43.60%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-56.33%Sep 8, 2021540Oct 30, 2023
-27.15%Mar 5, 20208Mar 16, 202025Apr 24, 202033
-26.01%Feb 16, 202115Mar 8, 2021101Jul 30, 2021116
-8.87%Sep 3, 20203Sep 8, 202019Oct 5, 202022
-8.02%Oct 14, 202014Nov 2, 20203Nov 5, 202017

Volatility

Volatility Chart

The current Franklin Genomic Advancements ETF volatility is 3.35%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%OctoberNovemberDecember2024FebruaryMarch
3.35%
2.80%
HELX (Franklin Genomic Advancements ETF)
Benchmark (^GSPC)